ATXS
Price
$5.81
Change
+$0.08 (+1.40%)
Updated
Jul 3 closing price
Capitalization
327.88M
38 days until earnings call
FENC
Price
$8.80
Change
+$0.26 (+3.04%)
Updated
Jul 3 closing price
Capitalization
240.63M
34 days until earnings call
Interact to see
Advertisement

ATXS vs FENC

Header iconATXS vs FENC Comparison
Open Charts ATXS vs FENCBanner chart's image
Astria Therapeutics
Price$5.81
Change+$0.08 (+1.40%)
Volume$188.85K
Capitalization327.88M
Fennec Pharmaceuticals
Price$8.80
Change+$0.26 (+3.04%)
Volume$80.32K
Capitalization240.63M
ATXS vs FENC Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FENC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. FENC commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and FENC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (ATXS: $5.81 vs. FENC: $8.80)
Brand notoriety: ATXS and FENC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 43% vs. FENC: 88%
Market capitalization -- ATXS: $327.88M vs. FENC: $240.63M
ATXS [@Biotechnology] is valued at $327.88M. FENC’s [@Biotechnology] market capitalization is $240.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileFENC’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • FENC’s FA Score: 0 green, 5 red.
According to our system of comparison, FENC is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 6 TA indicator(s) are bullish while FENC’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 6 bullish, 4 bearish.
  • FENC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than FENC.

Price Growth

ATXS (@Biotechnology) experienced а +6.80% price change this week, while FENC (@Biotechnology) price change was +6.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

FENC is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($328M) has a higher market cap than FENC($241M). FENC YTD gains are higher at: 39.241 vs. ATXS (-35.011). FENC has higher annual earnings (EBITDA): -10.34M vs. ATXS (-124.4M). ATXS has more cash in the bank: 295M vs. FENC (22.7M). ATXS has less debt than FENC: ATXS (5.06M) vs FENC (19.4M). FENC has higher revenues than ATXS: FENC (30.9M) vs ATXS (0).
ATXSFENCATXS / FENC
Capitalization328M241M136%
EBITDA-124.4M-10.34M1,203%
Gain YTD-35.01139.241-89%
P/E RatioN/A64.14-
Revenue030.9M-
Total Cash295M22.7M1,300%
Total Debt5.06M19.4M26%
FUNDAMENTALS RATINGS
ATXS vs FENC: Fundamental Ratings
ATXS
FENC
OUTLOOK RATING
1..100
698
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
90
Overvalued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
5839
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (58) in the Biotechnology industry is in the same range as FENC (90). This means that ATXS’s stock grew similarly to FENC’s over the last 12 months.

FENC's Profit vs Risk Rating (88) in the Biotechnology industry is in the same range as ATXS (100). This means that FENC’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's SMR Rating (96) in the Biotechnology industry is in the same range as FENC (100). This means that ATXS’s stock grew similarly to FENC’s over the last 12 months.

FENC's Price Growth Rating (39) in the Biotechnology industry is in the same range as ATXS (58). This means that FENC’s stock grew similarly to ATXS’s over the last 12 months.

FENC's P/E Growth Rating (98) in the Biotechnology industry is in the same range as ATXS (100). This means that FENC’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSFENC
RSI
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
75%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 8 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
75%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FENC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMLM0.03N/A
+13.80%
American Lithium Minerals, Inc.
DNGDF3.360.05
+1.42%
Dynacor Group Inc.
XYIGY21.00N/A
N/A
Xinyi Glass Holdings Ltd.
IOOFF1.30N/A
N/A
Insignia Financial Ltd.
RCRRF54.38-5.37
-8.99%
Recruit Holdings Co., Ltd.

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with XENE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+1.40%
XENE - ATXS
53%
Loosely correlated
-0.33%
CRNX - ATXS
53%
Loosely correlated
+1.22%
DNLI - ATXS
52%
Loosely correlated
-1.41%
ERAS - ATXS
52%
Loosely correlated
-0.69%
COGT - ATXS
52%
Loosely correlated
+2.29%
More

FENC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FENC has been loosely correlated with DNLI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if FENC jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FENC
1D Price
Change %
FENC100%
+3.04%
DNLI - FENC
46%
Loosely correlated
-1.41%
BEAM - FENC
45%
Loosely correlated
+0.65%
CLDX - FENC
45%
Loosely correlated
-0.50%
IDYA - FENC
44%
Loosely correlated
+0.82%
ATXS - FENC
42%
Loosely correlated
+1.40%
More